Compare EXLS & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | BLLN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 65000 | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.4B |
| IPO Year | 2004 | 2025 |
| Metric | EXLS | BLLN |
|---|---|---|
| Price | $35.30 | $117.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $46.80 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.7M | 495.8K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 103.40 |
| EPS | 0.43 | ★ 0.48 |
| Revenue | N/A | ★ $305,112,000.00 |
| Revenue This Year | $12.61 | $46.29 |
| Revenue Next Year | $10.55 | $30.14 |
| P/E Ratio | ★ $82.00 | $216.38 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $24.85 | $61.96 |
| 52 Week High | $44.32 | $150.44 |
| Indicator | EXLS | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 51.97 |
| Support Level | $34.33 | $79.07 |
| Resistance Level | $36.55 | $108.50 |
| Average True Range (ATR) | 0.85 | 4.98 |
| MACD | -0.31 | 1.52 |
| Stochastic Oscillator | 34.11 | 54.91 |
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.